profit from every ₹100 of sales.
₹0₹100
Shilpa Medicare
₹993.10+0.58% today
+206.7% in 1 year
1-year low ₹266.401-year high ₹1,072.45
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹79.82 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Shilpa Medicare sold, what it kept, and what it did with the cash.
Sales went from ₹10.4 billion in 2023 to ₹15.4 billion in 2026, with ₹2.43 billion of profit last year.
SalesProfit
Shilpa Medicare vs. similar companies
Shilpa Medicare grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Shilpa Medicare | 79.8× · Very expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Shilpa Medicare's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 10,434 | 11,516 | 12,864 | 15,389 | |
| 6,266 | 7,428 | 8,760 | 10,785 | |
| -46 | 1,339 | 2,438 | 3,759 | |
| 1,135 | 2,459 | 3,483 | 5,348 | |
| -325 | 319 | 783 | 2,433 | |
| -1.88 | 1.84 | 4.02 | – | |
| 60.1% | 64.5% | 68.1% | 70.1% | |
| -0.4% | 11.6% | 19.0% | 24.4% | |
| -3.1% | 2.8% | 6.1% | 15.8% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 29,039 | 30,932 | 33,107 | 37,056 |
| Cash | 213 | 302 | 260 | 413 |
| Total debt | 7,979 | 9,374 | 5,877 | 6,599 |
| Total liabilities | 11,296 | 12,933 | 9,470 | 11,144 |
| 17,833 | 18,011 | 23,631 | 25,912 | |
| 174 | 174 | 195 | – | |
| 0.6% | 4.0% | 6.3% | 10.1% | |
| -1.8% | 1.8% | 3.3% | 9.4% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,799 | 1,367 | 1,323 | 3,422 | |
| 2,267 | 1,846 | 2,437 | 3,706 | |
| -467 | -479 | -1,114 | -285 | |
| Dividends paid | 95 | – | – | 98 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 79.8×
- –
- –
- 4.1×
- 12.6×
- –
- 37.5×
- -0.1%
- 1.3%
- 0.1%
Profitability
- 70.1%
- 24.4%
- 15.8%
- –
- 9.6%
- 5.0%
- –
- –
- –
- –
Growth
- +13.8%
- –
- –
- –
- +5.2%
Financial health
- 1.2×
- 0.25
- –
- 3.5×
- 1.31
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 32%of 963
Top 17%of 894
Bottom 13%of 632
Top 40%of 908
Bottom 36%of 991
0.1%of the share price, paid each year
On $1,000 invested$1a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
4.0% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
19No pass
Philip Fisher
40No pass
Peter Lynch
74Pass
Joel Greenblatt
6No pass
Charlie Munger
31No pass
Terry Smith
28No pass
Questions about Shilpa Medicare
Is Shilpa Medicare a good stock to buy?
A solid business, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Shilpa Medicare AI analysis
What does Shilpa Medicare do?
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Raichur, India.
Does Shilpa Medicare pay a dividend?
Yes. At today's price the dividend is 0.1% a year, about 4% of its yearly profit. In 2026 it paid out ₹97.8 million in dividends.
Is Shilpa Medicare stock halal?
Yes. Shilpa Medicare passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Shilpa Medicare stock done over the past year?
Up 206.7% over the past twelve months, to ₹993.10. It traded between ₹266.40 and ₹1,072.45 and is 7.4% below its high.
Who are Shilpa Medicare's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Shilpa Medicare's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.